Drug Discovery

announcements

March 4, 2020

Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute Invite Proposals for 2020

The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, or slow Alzheimer's disease or related dementias.

blog

December 10, 2019

Stepping Forward in Alzheimer’s Disease Research: A Combination Therapy Approach

Chief Medical Officer at Amylyx Pharmaceuticals gives a closer look at how far they have come in their recently expanded phase 2 clinical trial, supported in part by the ADDF, which is studying a combination approach to treating people with Alzheimer’s disease.

announcements

October 22, 2019

Alzheimer’s Drug Discovery Foundation Statement on Biogen Announcement to Plan FDA Filing of Aducanu

The Alzheimer’s Drug Discovery Foundation is encouraged by today’s announcement from Biogen of its plans to seek regulatory approval for aducanumab as a potential new treatment for Alzheimer’s disease, particularly for people living with the early stages of Alzheimer’s.

announcements

October 17, 2019

Alzheimer’s Drug Discovery Foundation Partners with Shionogi and Janssen Pharmaceuticals for its Dia

The Alzheimer’s Drug Discovery Foundation (ADDF) announced a partnership with Shionogi & Co., Ltd. and Janssen Pharmaceuticals, Inc. as part of its Diagnostics Accelerator, an initiative that aims to fast-track the development of novel biomarkers for the early detection of Alzheimer's disease and related dementias.

announcements

October 15, 2019

$3.2 Million in New Funding Focused on Biomarkers and Moving Toward New Therapies

These recent investments reflect the ADDF's commitment to advancing tools for early detection, with an emphasis on exploring the different pathologies associated with aging.

announcements

September 23, 2019

20th International Conference on Alzheimer’s Drug Discovery Showcases Diversity of Approaches

announcements

May 10, 2019

$7.1 Million in New Funding Illustrates the ADDF’s Strong Support of a Diverse Pipeline

The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.

announcements

July 13, 2018

New Investments Fund Research Ranging from Novel Treatments for Postoperative Cognitive Dysfunction

The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.

announcements

May 10, 2018

$2.5 Million in New Funding Exemplifies ADDF’s Strategy

We announce $2.5 million in new funding, which reflects the comprehensive nature of our strategy to prevent and treat Alzheimer’s disease.

announcements

March 28, 2018

ADDF and Harrington Discovery Institute Invite Applications for 2018 ADDF-Harrington Scholar Award

Harrington Discovery Institute and the Alzheimer’s Drug Discovery Foundation (ADDF) announce a request for proposals for the 2018 ADDF-Harrington Scholar Award.

announcements

March 13, 2018

Funding Supports New Approaches to Treat Multiple Types of Dementia

The ADDF announces two investments in programs targeting mitochondria and the progranulin gene.

announcements

November 14, 2017

Three New Grants Keep Promising Programs Forging Ahead

The Alzheimer’s Drug Discovery Foundation (ADDF) announces three new investments, all of which are for programs that the ADDF previously funded.

announcements

October 3, 2017

New Project Co-Funded with Pfizer’s Centers for Therapeutic Innovation

The Alzheimer's Drug Discovery Foundation (ADDF) and Pfizer's Centers for Therapeutic Innovation (CTI) announced joint support for a project that could result in a therapeutic for neurodegenerative diseases.

announcements

September 5, 2017

New Funding Supports Blood Test for Early Alzheimer’s

The ADDF announces two new grants, including support for a blood test designed to detect Alzheimer’s disease in early stages of development and a gene therapy for frontotemporal dementia.

blog

August 17, 2017

Inflammation, The Driver of Alzheimer’s Disease?

A growing body of evidence suggests that inflammation in the brain is implicated in the development of Alzheimer's.

announcements

July 11, 2017

Latest Funding Includes Support for Innovative Clinical Trial

The ADDF announces four new grants, including support for an innovative clinical trial, two novel drug programs, and a biomarker for CTE.

announcements

June 29, 2017

2016 Annual Report Released

The 2016 Annual Report, titled “From Idea to Impact,” highlights the enormous progress the ADDF has made toward finding effective treatments for Alzheimer’s disease.

announcements

June 7, 2017

ADDF and Science Exchange Launch ADDF ACCESS to Advance Research

New “CRO Finder” Connects Scientists with Specialized Resources

announcements

March 7, 2017

$4 Million in New Grants Support Several First-in-Class Dementia Treatments

We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.

announcements

January 18, 2017

Expanded Partnership Increases Support for Drug Discovery

ADDF and Harrington Institute increase funding and resources for promising Alzheimer’s drug discovery programs.

announcements

January 9, 2017

$2.5 Million in New Grants Advance Clinical Trials of Alzheimer’s Treatments

We awarded three new grants in November and December, totaling nearly $2.5 million. The grants represent our commitment to advancing the most promising drugs to clinical trials, the final stages of drug development.

announcements

November 8, 2016

$1.5 Million in New Grant Funding for Promising Treatments

The Alzheimer’s Drug Discovery Foundation awarded three new grants in September and October totaling nearly $1.5 million.

announcements

September 22, 2016

Vivreon Biosciences Awarded Grant to Advance Drug Program Targeting Neuroinflammation

Vivreon Biosciences, LLC has been awarded a preclinical drug discovery grant from the Alzheimer's Drug Discovery Foundation (ADDF) to develop compounds that targets brain inflammation in Alzheimer's disease.

announcements

September 21, 2016

$1.7 Million Grant Supports Promising Drug That Targets Cannabinoid Receptor

With a $1.7 million award from the ADDF, a new biotech created by Cleveland Clinic Innovations is developing a novel drug that reduces inflammation in the brain by targeting a cannabinoid receptor.

announcements

September 13, 2016

Dr. D. Martin Watterson Wins Second Melvin R. Goodes Prize

Dr. Watterson has identified a number of new classes of Central Nervous System drugs.